SCHEMBL1241024

SCHEMBL1241024

CN(c1ccc(F)c(Cl)c1)C1CCCC1

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
AXL P30530 1/20 0.40
ALDH1A1 P00352 1/20 0.40
SLC6A2 P23975 1/20 0.39
SLC6A4 P31645 1/20 0.39
SLC6A3 Q01959 1/20 0.39
TAS1R3 Q7RTX0 1/20 0.39
TAS1R1 Q7RTX1 1/20 0.39
TAS1R2 Q8TE23 1/20 0.39
POLQ O75417 4/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
FPR2 P25090 1/20 0.38
PROKR1 Q8TCW9 1/20 0.38
S1PR3 Q99500 1/20 0.36
TSHR P16473 2/20 0.35
HPGD P15428 1/20 0.35
TRPA1 O75762 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27599635 0.84 FPR2 (0.48) ALDH1A1SLC6A2SLC6A4SLC6A3NPC1
SCHEMBL1241520 0.84 S1PR3 (0.39) ALDH1A1SLC6A2SLC6A4SLC6A3TAS1R3
SCHEMBL1241993 0.83 S1PR3 (0.39) SLC6A2SLC6A4SLC6A3TAS1R3TAS1R1
SCHEMBL1241082 0.82 CHRM5 (0.39) SLC6A2SLC6A4SLC6A3TAS1R3TAS1R1
SCHEMBL27576244 0.80 POLB (0.46) ALDH1A1NPC1RAB9AFPR2PROKR1
SCHEMBL29161898 0.79 JAK3 (0.35) ALDH1A1SLC6A2SLC6A4SLC6A3RAB9A
SCHEMBL1240988 0.79 TAS1R3 (0.42) TAS1R3TAS1R1TAS1R2S1PR3TRPA1
SCHEMBL1242070 0.78 ALDH1A1 (0.44) ALDH1A1TSHRHPGD
SCHEMBL1240840 0.74 KMT2A (0.44) ALDH1A1RAB9ATSHR
SCHEMBL1042543 0.74 ALDH1A1 (0.47) ALDH1A1SLC6A2SLC6A4SLC6A3TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8586614-B2 Urea glucokinase activators NOVO NORDISK A/S (DK) 2013-11-19 US disclosed
CN-101263131-B Urea glucokinase activators TRANSTECH PHARMA INC 2013-04-24 CN disclosed
US-20110077234-A1 Urea Glucokinase Activators NOVO NORDISK A/S (DK) 2011-03-31 US disclosed
US-7884210-B2 {2-[3-(2-Cyclohex-1-enyl-ethyl)-3-(trans-4-methyl-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid; for treatment of type 2 diabetes NOVO NORDISK A/S (DK) 2011-02-08 US disclosed
US-20090105482-A1 Urea Glucokinase Activators NOVO NORDISK A/S (DK) 2009-04-23 US disclosed
CN-101263131-A Urea glucokinase activators NOVO NORDISK AS (US) 2008-09-10 CN disclosed
EP-1904467-A1 UREA GLUCOKINASE ACTIVATORS Novo Nordisk A/S (DK) 2008-04-02 EP disclosed
WO-2007006814-A1 UREA GLUCOKINASE ACTIVATORS NOVO NORDISK A/S (DK) 2007-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105482-A1 Urea Glucokinase Activators GCK, GCKR, HK2 AXL 1041/4885ALDH1A1 1040/4885SLC6A2 2953/4885
US-20110077234-A1 Urea Glucokinase Activators GCK, GCKR, HK2 AXL 1041/4885ALDH1A1 1040/4885SLC6A2 2953/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.